대한한방내과학회지 (The Journal of Internal Korean Medicine)

대한한방내과학회 (The Society of Internal Korean Medicine)
권호 표지
DOI QR코드

DOI QR Code

통합암치료를 적용한 난소암 뇌, 척추전이 환자의 5년 추적관찰 증례보고

Five-Year Follow-up of an Ovarian Cancer Patient with Brain and Vertebral Metastasis Using Integrative Cancer Treatment: A Case Report

  • 배혜리 (대전대학교 부속 천안한방병원 동서암센터) ;
  • 김은지 (대전대학교 부속 천안한방병원 동서암센터) ;
  • 이남헌 (대전대학교 부속 천안한방병원 동서암센터)
  • Hye-ri Bae (East-West Cancer Center, Cheonan Korean Medical Hospital, Dae-Jeon University) ;
  • Eun-ji Kim (East-West Cancer Center, Cheonan Korean Medical Hospital, Dae-Jeon University) ;
  • Nam-hun Lee (East-West Cancer Center, Cheonan Korean Medical Hospital, Dae-Jeon University)
  • 투고 : 2023.11.30
  • 심사 : 2023.12.29
  • 발행 : 2023.12.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: This long-term case report presents the case of an ovarian cancer patient with brain, cervical lymph node, and vertebral metastasis suppressed by traditional Korean medicine in combination with cytokine-induced killer (CIK) cell-based immunotherapy. Methods: The patient received acupuncture, moxibustion, GunChil-go, Hangam-dan, and CIK cell-based immunotherapy. The Eastern Cooperative Oncology Group and tumor markers were used to evaluate the treatment effects. Results: Integrative cancer treatment suppressed the progression of cancer, and the patient achieved eight-year survival. The performance status improved, and the tumor marker level was maintained. Conclusions: We suggest that an integrative cancer treatment that includes traditional Korean medicine can be a meaningful treatment option for advanced ovarian cancer.

키워드

과제정보

이 연구는 대한민국 정부(과학기술정보통신부)의 재원으로 한국연구재단의 지원을 받아 수행된 연구임(RS-2023-00246351).

참고문헌

  1. The Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2021. Ministry of Health and Welfare 2023.
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70(1):7-30. https://doi.org/10.3322/caac.21590
  3. Modugno F, Edwards RP. Ovarian cancer: Prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report. Int J Gynecol Cancer 2012;22(8):1-22. https://doi.org/10.1097/IGC.0b013e318242de2c
  4. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet 2019;393(10177):1240-53. https://doi.org/10.1016/S0140-6736(18)32552-2
  5. No JH, Park YS, Kim SM, Chung HH, Kim JW, Park NH, et al. Pattern of care: epithelial ovarian cancer in case of incomplete previous surgery. Korean J Gynecol Oncol 2007;18(3):195-200. https://doi.org/10.3802/kjgo.2007.18.3.195
  6. Le T, Adolph A, Krepart GV, Lotocki R, Heywood MS. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol 2002;85(2):351-5. https://doi.org/10.1006/gyno.2002.6636
  7. Lim MC, Park SY. Chemotherapy for ovarian cancer. J Korean Med Assoc 2016;59(3):175-9. https://doi.org/10.5124/jkma.2016.59.3.175
  8. Kang SH, Hwang IH, Son EJ, Cho CK, Choi JS, Park SJ, et al. Allergen-Removed Rhus verniciflua Extract Induces Ovarian Cancer Cell Death via JNK Activation. Am J Chin Med 2016;44(8):1719-35. https://doi.org/10.1142/S0192415X16500968
  9. Jang HJ, Yang KE, Hwang IH, Huh YH, Kim DJ, Yoo HS, et al. Cordycepin inhibits human ovarian cancer by inducing autophagy and apoptosis through Dickkopf-related protein 1/β-catenin signaling. Am J Transl Res 2019;11(11):6890-906.
  10. Baiocchi G, Cestari LA, Macedo MP, Oliveira R, Fukazawa E, Faloppa C, et al. Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection. J Surg Oncol 2011;104(3):250-4. https://doi.org/10.1002/jso.21940
  11. Picaud L, Thibault B, Mery E, Ouali M, Martinez A, Delord JP, et al. Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progression. J Ovarian Res 2014;7:40.
  12. Chereau E, Ballester M, Rouzier R, Coutant C, Darai E. Advanced ovarian cancer: criteria of resectability. Bull Cancer 2009;96(12):1189-97. https://doi.org/10.1684/bdc.2009.0985
  13. Choi JH, Suh MJ, Park DT. The correlation of clusterin binding affinity to chemotherapeutic agents with chemoresistance in ovarian cancer cells. Korean J Obs Gynecol 2008;51(7):738-43.
  14. Salani R, Backes FJ, Fung MFK, Holschneider CH, Parker LP, Bristow RE, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011;204(6):466-78. https://doi.org/10.1016/j.ajog.2011.03.008
  15. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354(1):34-43. https://doi.org/10.1056/NEJMoa052985
  16. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95(2):105-12. https://doi.org/10.1093/jnci/95.2.105
  17. Chan KKL, Yao TJ, Jones B, Zhao JF, Ma FK, Leung CY, et al. The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol Off J Eur Soc Med Oncol 2011;22(10):2241-9. https://doi.org/10.1093/annonc/mdq749
  18. Wu YH, Chen HY, Lai CH, Yeh CS, Pang JHS, Qiu JT, et al. Use of Chinese Herbal Medicine Improves Chemotherapy-Induced Thrombocytopenia among Gynecological Cancer Patients: An Observational Study. Evid Based Complement Alternat Med 2018;2018:4201325.
  19. Wang R, Sun Q, Wang F, Liu Y, Li X, Chen T, et al. Efficacy and Safety of Chinese Herbal Medicine on Ovarian Cancer After Reduction Surgery and Adjuvant Chemotherapy: A Systematic Review and Meta-Analysis. Front Oncol 2019;9:730.
  20. Kim KS, Choi HS, Kim SM, Yoo HS. Clinical Practice Guideline for Korean Medicine for Ovarian Cancer. J of Kor Traditional Oncolog 2016;21(2):37-50.
  21. Lee NH, Yoon DH, Yoo HS, Cho JH, Son CG, Lee YW, et al. Changes of Serum VEGF, bFGF levels and platelet counts in 100 Cancer Patients treated with Hang-Am-Dan. The Journal of Internal Korean Medicine 2005;26(4):753-60.
  22. Yoo HS, Lee YY, Song KC, Choi BL, Seo SH, Cho JH, et al. The Effects of HangAmDan(HAD) on Anti-Metastasis and Preventing Relapses, Administered to 69 Cancer Patients. The Journal of Internal Korean Medicine 2002;23(2):165-73.
  23. Yoo HS, Son CG, Cho CK. Antitumor effects of HangAmDan (HAD) on 55 patients with advanced gastric cancer. J Korean Med 2001;2(1):77-88.
  24. Lee YY, Seo SH, Yoo HS, Choi WJ, Cho JH, et al. The Clinical study in 83 cases for colorectal cancer patients on the effects by Hangamdan(抗癌丹). Journal of Korean Traditional Oncology 2000;6(1):165-80.
  25. Choi WC, Jung HS, Kim KS, Lee SK, Yoon SW, Park JH, et al. Rhus verniciflua stokes against advanced cancer: A perspective from the korean integrative cancer center. J Biomed Biotechnol 2012;2012:874276.
  26. Ahn J, Lee JS, Yang KM. Ultrafine particles of Ulmus davidiana var. japonica induce apoptosis of gastric cancer cells via activation of caspase and endoplasmic reticulum stress. Arch Pharm Res 2014;37(6):783-92.
  27. Jin UH, Lee DY, Kim DS, Lee IS, Kim CH. Induction of mitochondria-mediated apoptosis by methanol fraction of Ulmus davidiana Planch (Ulmaceae) in U87 glioblastoma cells. Environ Toxicol Pharmacol 2006;22(2):136-41. https://doi.org/10.1016/j.etap.2006.01.005
  28. Baek I, Im LH, Park C, Cho YH. Anti-cancer Potentials of Rhus verniciflua Stokes, Ulmus davidiana var. japonica Nakai and Arsenium Sublimatum in Human Gastric Cancer AGS Cells. J Life Sci 2015;25(8):849-60. https://doi.org/10.5352/JLS.2015.25.8.849
  29. Kim JY, Kim JY, Kim NS, Kim SJ, Oyungerel M, Kim YS, et al. Review on Clinical Trials of Chemotherapy Induced Toxicity with Acupuncture in PubMed Database. Journal of Korean Acupuncture & Moxibustion Medicine Society 2013;30(2):43-53.
  30. Yoon HC, Kang JY, Kim JY, Joung JY, Son CG, Lee NH, et al. Trends in Treatment with and Mechanism of Moxibustion in Cancer Patients: A Review. J Int Korean Med 2015;36(3):361-79.
  31. Zhang Y, Schmidt-Wolf IGH. Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. J Cell Physiol 2020;235(12):9291-303. https://doi.org/10.1002/jcp.29827